Hydroxycitric acid-metal heterocyclic compounds with covalent characteristics are provided. The subject hydroxycitric acid compounds include monomeric hydroxycitric acid (HCA) compounds having a divalent metal, lactone forms thereof, and dimeric compound forms thereof. The monomeric HCA compound includes a divalent metal (X) bonded via a 5-membered ring to both the carboxylic acid and the hydroxy group of the central C2 carbon of the HCA. In addition, a monovalent metal (Y) can also be bonded to the carboxylic acid of C3 or C1, or to both C1 and C3. The subject dimeric compounds include monomeric HCA compounds linked via a second divalent metal (X) to a carboxylic acid group of each HCA unit at C3 or C1. Also provided are compositions including a monomeric HCA compound and one or more other additional compounds. Methods of alleviating at least one symptom associated with a target disease or condition in a subject are provided.

To provide a metal-containing additive and a crosslinkable polymer composition that each contain a -diketonato metal complex and have excellent storage stability, and provide a crosslinked polymer material, a metal member, and a wire harness that are each produced using such a crosslinkable polymer composition. The metal-containing additive includes the -diketonato metal complex and a primary alkyl alcohol having 4 to 30 carbon atoms. The crosslinkable polymer composition includes the metal-containing additive and an organic polymer, where the organic polymer has a substituent capable of forming ionic bonds with metal ions released by heat from the metal-containing additive.

The invention relates to a novel use of benzazepine, benzoxazepine, benzothiazepine-N-acetic acid and phosphono-substituted benzazepinone derivatives having both neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP), and endothelin convertase (ECE), inhibitory activity. The compounds of this invention are useful for the preparation of pharmaceutical compositions to reduce harmful effects of symptomless progressive disseminated perfusion deficiency of organs, or parts thereof, that may be suggestive of systemic diseases.

The invention relates to a novel use of benzazepine, benzoxazepine, benzothiazepine-N-acetic acid and phosphono-substituted benzazepinone derivatives having both neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP), and endothelin convertase (ECE), inhibitory activity. The compounds of this invention are useful for the preparation of pharmaceutical compositions to reduce harmful effects of symptomless progressive disseminated perfusion deficiency of organs, or parts thereof, that may be suggestive of systemic diseases.

A process to functionalized organo-metal compounds with silyl-based electrophiles. The process includes combining an organo-metal compound, a silyl-based functionalization agent, and an optional solvent. Functionalized silanes and silyl-terminated polyolefins can be prepared by this process.

A process to functionalized organo-metal compounds with silyl-based electrophiles. The process includes combining an organo-metal compound, a silyl-based functionalization agent, and an optional solvent. Functionalized silanes and silyl-terminated polyolefins can be prepared by this process.

The present disclosure is directed to a silicon-terminated organo-metal composition comprising a compound of formula (I). Embodiments relate to a process for preparing the silicon-terminated organo-metal composition comprising the compound of formula (I), the process comprising combining starting materials comprising (A) a vinyl-terminated silicon-based compound, (B) a chain shuttling agent, (C) a procatalyst, and (D) an activator, thereby obtaining a product comprising the silicon-terminated organo-metal composition. In further embodiments, the starting materials of the process may further comprise (E) a solvent and/or (F) a scavenger.

The present disclosure is directed to a silicon-terminated organo-metal composition comprising a compound of formula (I). Embodiments relate to a process for preparing the silicon-terminated organo-metal composition comprising the compound of formula (I), the process comprising combining starting materials comprising (A) a vinyl-terminated silicon-based compound, (B) a chain shuttling agent, (C) a procatalyst, and (D) an activator, thereby obtaining a product comprising the silicon-terminated organo-metal composition. In further embodiments, the starting materials of the process may further comprise (E) a solvent and/or (F) a scavenger.

The present disclosure generally relates to metal complex or metal chelate compositions comprising minimal nanoparticles wherein the compositions maintain flowability.

The present disclosure generally relates to metal complex or metal chelate compositions comprising minimal nanoparticles wherein the compositions maintain flowability.